EW vs REGN · P/E 47, rev $1.39B vs P/E 14, rev $14.34B
Edwards Lifesciences Corp (EW) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Edwards Lifesciences Corp (EW) is a medical devices company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported EW revenue for 2024-12-31 was $1.39B. Net income was $385.6M. Revenue was up 2.3% from 2024-09-30 to 2024-12-31. EW currently screens at market cap $49.91B and trailing P/E 46.9.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
EW currently screens at market cap $49.91B and trailing P/E 46.9. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the EW and REGN stock pages for the full models.
Not investment advice.